SI-BONE INC (SIBN) Stock Price, Forecast & Analysis

USA • Nasdaq • NASDAQ:SIBN • US8257041090

16.58 USD
+0.03 (+0.18%)
At close: Jan 30, 2026
16.58 USD
0 (0%)
After Hours: 1/30/2026, 8:18:51 PM

SIBN Key Statistics, Chart & Performance

Key Statistics
Market Cap719.41M
Revenue(TTM)193.58M
Net Income(TTM)-21.75M
Shares43.39M
Float39.55M
52 Week High21.89
52 Week Low12.5
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)-0.51
PEN/A
Fwd PEN/A
Earnings (Next)02-23
IPO2018-10-17
Sector
GICS SectorHealth Care
GICS IndustryHealth Care Equipment & Supplies
GICS IndustryGroupHealth Care Equipment & Services
GICS SubIndustryHealth Care Equipment
SIBN short term performance overview.The bars show the price performance of SIBN in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10 -15

SIBN long term performance overview.The bars show the price performance of SIBN in the last 1, 2 and 3 years. 1 year 2 years 3 years -5 -10 -15

The current stock price of SIBN is 16.58 USD. In the past month the price decreased by -15.92%. In the past year, price decreased by -1.07%.

SI-BONE INC / SIBN Daily stock chart

SIBN Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to SIBN. When comparing the yearly performance of all stocks, SIBN turns out to be only a medium performer in the overall market: it outperformed 56.23% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

SIBN Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to SIBN. The financial health of SIBN is average, but there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

SIBN Financial Highlights

Over the last trailing twelve months SIBN reported a non-GAAP Earnings per Share(EPS) of -0.51. The EPS increased by 44.57% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -9.29%
ROE -12.64%
Debt/Equity 0.21
Chartmill High Growth Momentum
EPS Q2Q%31.25%
Sales Q2Q%20.61%
EPS 1Y (TTM)44.57%
Revenue 1Y (TTM)23.27%

SIBN Forecast & Estimates

15 analysts have analysed SIBN and the average price target is 26.41 USD. This implies a price increase of 59.27% is expected in the next year compared to the current price of 16.58.

For the next year, analysts expect an EPS growth of 28.75% and a revenue growth 19.98% for SIBN


Analysts
Analysts84
Price Target26.41 (59.29%)
EPS Next Y28.75%
Revenue Next Year19.98%

SIBN Ownership

Ownership
Inst Owners99.59%
Ins Owners3.12%
Short Float %6.14%
Short Ratio3.89

About SIBN

Company Profile

SIBN logo image SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 349 full-time employees. The company went IPO on 2018-10-17. The firm specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The firm's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The firm's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.

Company Info

SI-BONE INC

471 El Camino Real, Suite 101

Santa Clara CALIFORNIA 95050 US

CEO: Jeffrey W. Dunn

Employees: 349

SIBN Company Website

SIBN Investor Relations

Phone: 14082070700

SI-BONE INC / SIBN FAQ

What does SIBN do?

SI-BONE, Inc. is a medical device company, which engages in the provision of a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of musculoskeletal disorders of the sacropelvic anatomy. The company is headquartered in Santa Clara, California and currently employs 349 full-time employees. The company went IPO on 2018-10-17. The firm specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The firm's products include a series of patented titanium implants, and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The firm's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.


Can you provide the latest stock price for SI-BONE INC?

The current stock price of SIBN is 16.58 USD. The price increased by 0.18% in the last trading session.


Does SI-BONE INC pay dividends?

SIBN does not pay a dividend.


What is the ChartMill rating of SI-BONE INC stock?

SIBN has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Can you provide the market cap for SI-BONE INC?

SI-BONE INC (SIBN) has a market capitalization of 719.41M USD. This makes SIBN a Small Cap stock.


What is the next earnings date for SIBN stock?

SI-BONE INC (SIBN) will report earnings on 2026-02-23, after the market close.